Harmony Biosciences (HRMY) Tops Q4 EPS by 39c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts HRMY Hot Sheet
Join SI Premium – FREE
Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $1.08, $0.39 better than the analyst estimate of $0.69. Revenue for the quarter came in at $201.3 million versus the consensus estimate of $198.6 million.
GUIDANCE:
Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $844.4 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldcana closes $1M private placement of flow-through shares
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
